AU2013246485A1 - Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents - Google Patents

Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents Download PDF

Info

Publication number
AU2013246485A1
AU2013246485A1 AU2013246485A AU2013246485A AU2013246485A1 AU 2013246485 A1 AU2013246485 A1 AU 2013246485A1 AU 2013246485 A AU2013246485 A AU 2013246485A AU 2013246485 A AU2013246485 A AU 2013246485A AU 2013246485 A1 AU2013246485 A1 AU 2013246485A1
Authority
AU
Australia
Prior art keywords
formula
compound
enantiomers
heteroaryl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013246485A
Other languages
English (en)
Inventor
Sultan Chowdhury
Jianmin Fu
Michael Edward Grimwood
Ivan William Hemeon
Tarek Suhayl Mansour
Shaoyi Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xenon Pharmaceuticals Inc
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of AU2013246485A1 publication Critical patent/AU2013246485A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2013246485A 2012-04-12 2013-03-11 Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents Abandoned AU2013246485A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261623336P 2012-04-12 2012-04-12
US61/623,336 2012-04-12
PCT/US2013/030219 WO2013154712A1 (en) 2012-04-12 2013-03-11 Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents

Publications (1)

Publication Number Publication Date
AU2013246485A1 true AU2013246485A1 (en) 2014-10-16

Family

ID=47902379

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013246485A Abandoned AU2013246485A1 (en) 2012-04-12 2013-03-11 Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents

Country Status (14)

Country Link
US (2) US9487535B2 (cg-RX-API-DMAC10.html)
EP (1) EP2838902B1 (cg-RX-API-DMAC10.html)
JP (1) JP6195609B2 (cg-RX-API-DMAC10.html)
KR (1) KR20150002794A (cg-RX-API-DMAC10.html)
CN (2) CN104350057A (cg-RX-API-DMAC10.html)
AU (1) AU2013246485A1 (cg-RX-API-DMAC10.html)
CA (1) CA2869547A1 (cg-RX-API-DMAC10.html)
EA (1) EA201491854A1 (cg-RX-API-DMAC10.html)
ES (1) ES2714314T3 (cg-RX-API-DMAC10.html)
HK (3) HK1205114A1 (cg-RX-API-DMAC10.html)
IL (1) IL235006A0 (cg-RX-API-DMAC10.html)
MX (1) MX2014012266A (cg-RX-API-DMAC10.html)
WO (1) WO2013154712A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201407334B (cg-RX-API-DMAC10.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20150882T1 (hr) 2008-10-17 2015-09-25 Xenon Pharmaceuticals Inc. Spirooksindolski spojevi i njihova upotreba kao terapijska sredstva
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
PE20170202A1 (es) 2009-10-14 2017-03-24 Xenon Pharmaceuticals Inc Metodos sinteticos para compuestos espiro-oxoindol
RU2596488C2 (ru) 2010-02-26 2016-09-10 Ксенон Фармасьютикалз Инк. Фармацевтические композиции спиро-оксиндольного соединения для местного введения и их применение в качестве терапевтических агентов
KR20150002794A (ko) 2012-04-12 2015-01-07 제논 파마슈티칼스 인크. 치료제로서 유용한 스파이로-옥시인돌 화합물을 위한 비대칭적 합성
WO2016109795A1 (en) 2014-12-31 2016-07-07 Concert Pharmaceuticals, Inc. Deuterated funapide and difluorofunapide
AR103636A1 (es) 2015-02-05 2017-05-24 Teva Pharmaceuticals Int Gmbh Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
WO2017180248A1 (en) * 2016-04-15 2017-10-19 William Marsh Rice University Enantioenriched viridicatumtoxin b analogs
EP3468545B1 (en) 2016-06-08 2026-08-05 President and Fellows of Harvard College Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, rett syndrome, and fragile x syndrome
WO2017218920A1 (en) 2016-06-16 2017-12-21 Teva Pharmaceuticals International Gmbh Asymmetric synthesis of funapide
CN109311905A (zh) * 2016-06-16 2019-02-05 泽农医药公司 螺-吲哚酮化合物的固态形式
CN108395438A (zh) * 2018-04-03 2018-08-14 陕西科技大学 一类具有抗菌活性的靛红母核螺环化合物及其合成方法
WO2019226808A1 (en) 2018-05-22 2019-11-28 President And Fellows Of Harvard College Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment
EP3801512A4 (en) 2018-05-29 2022-01-19 President and Fellows of Harvard College COMPOSITIONS AND METHODS TO REDUCE TACTILE DYSFUNCTION, ANXIETY AND SOCIAL DISABILITIES
US12077512B2 (en) 2019-03-25 2024-09-03 President And Fellows Of Harvard College Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment
CN116057045B (zh) 2020-06-05 2026-06-09 金耐特生物制药公司 成纤维细胞生长因子受体激酶抑制剂
US12552808B2 (en) 2020-09-03 2026-02-17 Amgen Inc. Diol desymmetrization by nucleophilic aromatic substitution

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3723459A (en) 1971-04-23 1973-03-27 Mc Neil Labor Inc 2-oxospiro (indoline -3,4{40 -thiochroman) derivatives
JPS6130554A (ja) 1984-07-23 1986-02-12 Ono Pharmaceut Co Ltd プロスタグランジン類似化合物のある特定の立体配置を有する異性体及びそれらを有効成分として含有する治療剤
DE3608088C2 (de) 1986-03-07 1995-11-16 Schering Ag Pharmazeutische Präparate, enthaltend Cyclodextrinclathrate von Carbacyclinderivaten
JP2716986B2 (ja) 1987-07-17 1998-02-18 シエーリング アクチエンゲゼルシヤフト 9‐ハロゲン‐(z)‐プロスタグランジン誘導体、その製法及び薬剤としてのその使用
US5314685A (en) 1992-05-11 1994-05-24 Agouron Pharmaceuticals, Inc. Anhydrous formulations for administering lipophilic agents
NO317155B1 (no) 1997-02-04 2004-08-30 Ono Pharmaceutical Co <omega>-cykloalkyl-prostagladin-E<N>2</N>-derivater
ATE237587T1 (de) 1997-02-10 2003-05-15 Ono Pharmaceutical Co 11,15-o-dialkylprostaglandin-e-derivate, verfahren zu ihrer herstellung und arzneimittel, die diese als aktiven inhaltsstoff enthalten
WO1999033794A1 (en) 1997-12-25 1999-07-08 Ono Pharmaceutical Co., Ltd. φ-CYCLOALKYL-PROSTAGLANDIN E2 DERIVATIVES
JP4087938B2 (ja) 1998-02-04 2008-05-21 高砂香料工業株式会社 ヒノキチオ−ル類の分岐サイクロデキストリン包接化合物からなる抗菌剤およびそれを含有する組成物
US6235780B1 (en) 1998-07-21 2001-05-22 Ono Pharmaceutical Co., Ltd. ω-cycloalkyl-prostaglandin E1 derivatives
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds
JPWO2005035498A1 (ja) 2003-10-08 2006-12-21 住友製薬株式会社 含窒素二環性化合物の摂食調節剤としての用途
JP2007536283A (ja) 2004-05-05 2007-12-13 ユニバイオスクリーン エス.アー. ナフタルイミド誘導体、それらの製造方法、およびそれらの医薬組成物
MY144968A (en) 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
AR053710A1 (es) 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
SI1924264T1 (sl) 2005-09-01 2013-12-31 F. Hoffmann-La Roche Ag Diaminopirimidini kot modulatorji p2x3 in p2x2/3
WO2007081895A2 (en) * 2006-01-09 2007-07-19 Merck & Co., Inc. Preparation of substituted 2-hydroxygibba-1(10a), 2, 4, 4b-tetraen-6-ones
WO2008046049A1 (en) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-c] pyridine-3-3 ' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
WO2008046087A2 (en) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Spiro compounds and their uses as therapeutic agents
EP2073806B1 (en) 2006-10-12 2012-02-15 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
BRPI0719166A2 (pt) 2006-10-12 2014-06-03 Xenon Pharmaceuticals Inc Derivados de espiro-oxindol tricíclicos e seus usos como agentes terapêuticos
GB0704846D0 (en) 2007-03-13 2007-04-18 Futura Medical Dev Ltd Topical pharmaceutical formulation
WO2010045197A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals, Inc. Spiro-oxindole compounds and their use as therapeutic agents
HRP20150882T1 (hr) 2008-10-17 2015-09-25 Xenon Pharmaceuticals Inc. Spirooksindolski spojevi i njihova upotreba kao terapijska sredstva
US20110269788A1 (en) 2008-12-29 2011-11-03 Xenon Pharmaceuticals Inc. Spiro-oxindole-derivatives as sodium channel blockers
US8295257B2 (en) 2009-03-13 2012-10-23 Telcordia Technologies, Inc. Scalable disruptive-resistant communication method
WO2010132352A2 (en) * 2009-05-11 2010-11-18 Xenon Pharmaceuticals Inc. Spiro compounds and their use as therapeutic agents
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
PE20170202A1 (es) 2009-10-14 2017-03-24 Xenon Pharmaceuticals Inc Metodos sinteticos para compuestos espiro-oxoindol
US20110086899A1 (en) 2009-10-14 2011-04-14 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
RU2596488C2 (ru) 2010-02-26 2016-09-10 Ксенон Фармасьютикалз Инк. Фармацевтические композиции спиро-оксиндольного соединения для местного введения и их применение в качестве терапевтических агентов
KR20150002794A (ko) 2012-04-12 2015-01-07 제논 파마슈티칼스 인크. 치료제로서 유용한 스파이로-옥시인돌 화합물을 위한 비대칭적 합성

Also Published As

Publication number Publication date
KR20150002794A (ko) 2015-01-07
IL235006A0 (en) 2014-12-31
WO2013154712A1 (en) 2013-10-17
EP2838902A1 (en) 2015-02-25
US20130274483A1 (en) 2013-10-17
CN104350057A (zh) 2015-02-11
US9487535B2 (en) 2016-11-08
ZA201407334B (en) 2017-05-31
HK1226389A1 (zh) 2017-09-29
JP2015516389A (ja) 2015-06-11
EA201491854A1 (ru) 2015-03-31
US20170066777A1 (en) 2017-03-09
ES2714314T3 (es) 2019-05-28
CN105753877A (zh) 2016-07-13
HK1205114A1 (en) 2015-12-11
JP6195609B2 (ja) 2017-09-13
CA2869547A1 (en) 2013-10-17
MX2014012266A (es) 2014-12-05
EP2838902B1 (en) 2018-12-05
HK1205113A1 (en) 2015-12-11

Similar Documents

Publication Publication Date Title
EP2838902B1 (en) Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents
CA2807034C (en) C-aryl glucoside derivatives, preparation process and pharmaceutical use thereof
TWI457122B (zh) 作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3-二氫苯並[1,4]戴奧辛-2-基甲基衍生物
TWI588136B (zh) 多環類衍生物、其製備方法及其在醫藥上的應用
DE60222742T2 (de) Beta-lactam-verbindungen,herstellungsverfahren für diese verbindungen und serumhypocholesterinämiemittel, die diese verbindungen enthalten
AU2016213768B2 (en) Chemical process
EA020209B1 (ru) Способ получения соединений, применимых в качестве ингибиторов натрийзависимого переносчика глюкозы
EA028946B1 (ru) Способ получения соединений для применения в качестве ингибиторов sglt2
EP1950211A1 (en) Process for production of cinnamamide derivative
AU2010324983A1 (en) Novel compounds as receptor modulators with therapeutic utility
WO2020129899A1 (ja) C-アリールヒドロキシグリコキシド誘導体の製造方法
JP2879147B2 (ja) 新規な抗高血圧性ベンゾピラン誘導体
JP2011519343A5 (cg-RX-API-DMAC10.html)
JP2011519343A (ja) Trpv3モジュレーターとしてのクロマン誘導体
EP0419247A2 (en) Selective GABA antagonists, especially isoquinoline derivatives, and their use for treating CNS disorders
OA11456A (en) Benzopyran and related LTB4 antagonists.
EP0402150A1 (en) New 2,5-diaryl tetrahydrofurans and analogs therof as PAF antagonists
Chandrasekhar et al. Practical and highly stereoselective approaches to the total synthesis of (−)-codonopsinine
JPS60218389A (ja) スワインソニンの製造方法
EP0980867A1 (en) Ketone derivatives and medicinal use thereof
Zhang et al. Supplementary Information for Nickel-Catalyzed Deaminative Sonogashira Coupling of Alkylpyridinium Salts Enabled by a New NN2 Pincer Ligand
JPS62153289A (ja) 2,6−エポキシ−3,4,5,6−テトラヒドロ−2H−ナフタレノ〔1,2−b〕オキソシン−9,12−ジオン誘導体
HK1170241A1 (zh) 可用作sglt2的抑制剂的化合物的制备方法
HK1170241B (en) Process for the preparation of compounds useful as inhibitors of sglt2
EP0083093A2 (en) Process and intermediates of octahydrobenzofuro(3,2-e)isoquinolines

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted